Abionyx PharmaFRA:609 -3.16%19 Days Inventory is 25.79 as of Dec. 2025, which is 21% above its 10-year median of 21.27. GuruFocus rates FRA:609 with a GF Score™ of 19/100 and a GF Value™ of €0.82 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 638 Biotechnology companies, Abionyx Pharma ranks better than 94.36% on this metric.
The historical rank and industry rank for Abionyx Pharma's Days Inventory or its related term are showing as below:
FRA:609'
s Days Inventory Range Over the Past 10 Years
Min: 12.81 Med: 21.27 Max: 155.3
Current: 23.24
During the past 13 years, Abionyx Pharma's highest Days Inventory was 155.30. The lowest was 12.81. And the median was 21.27.
FRA:609's Days Inventory is ranked better than 94.36% of 638
companies
in the Biotechnology industry
Industry Median: 183.875
vs FRA:609: 23.24
Abionyx Pharma's Days Inventory
increased
from Dec. 2024 (22.57) to Dec. 2025 (25.79).
It might indicate that Abionyx Pharma's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Abionyx Pharma's Inventory Turnover for the
six
months ended in Dec. 2025 was 7.08.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Abionyx Pharma's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.12.
Abionyx Pharma (FRA:609) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Abionyx Pharma's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Abionyx Pharma's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Abionyx Pharma Days Inventory Related Terms
Abionyx Pharma Days Inventory Historical Data
* Premium members only.
The historical data trend for Abionyx Pharma's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:609 vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Abionyx Pharma's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abionyx Pharma Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abionyx Pharma's Days Inventory distribution charts can be found below:
* The bar in red indicates where Abionyx Pharma's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abionyx Pharma (FRA:609) has a Days Inventory of 25.79 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Abionyx Pharma and its competitors. This is 21% above median its historical median of 21.27. Over the past decade, Abionyx Pharma's Days Inventory has ranged from 12.81 to 155.30. According to the industry distribution chart, Abionyx Pharma ranks #36 out of 638 companies in the Biotechnology industry, placing it in the top 5.6%.
Is Abionyx Pharma's Days Inventory too high?
Abionyx Pharma's current Days Inventory of 25.79 is 21% above median its 10-year median of 21.27. Over the past 10 years, this metric has ranged from a low of 12.81 to a high of 155.30. The Biotechnology industry median Days Inventory is 183.88. Abionyx Pharma's value of 25.79 is 86% below this industry median. Based on the distribution chart, Abionyx Pharma ranks #36 out of 638 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Abionyx Pharma has a GF Score™ of 19/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Abionyx Pharma's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Abionyx Pharma ranks #36 out of 638 companies for Days Inventory. This places Abionyx Pharma in the top 6% of its industry — outperforming the majority of peers. The industry median Days Inventory is 183.88. Abionyx Pharma's value of 25.79 is 86% below this benchmark. Historically, Abionyx Pharma's own Days Inventory has ranged from 12.81 to 155.30 over the past decade. While the company's 10-year median is 21.27 vs. the industry median of 183.88, Abionyx Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.88, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abionyx Pharma's current Days Inventory of 25.79 is 86% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Abionyx Pharma and its competitors. For the Biotechnology industry, the median Days Inventory is 183.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abionyx Pharma's current Days Inventory is 25.79, which is 21% above median its own 10-year median of 21.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abionyx Pharma stock overvalued right now?
Based on GuruFocus' analysis, Abionyx Pharma (FRA:609) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.82, compared to a current price of €1.99 — trading 142.7% above its estimated fair value. The current Days Inventory is 25.79, which is 21% above median its 10-year median of 21.27 and 86% below the Biotechnology industry median of 183.88. Abionyx Pharma's overall GF Score™ is 19/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Abionyx Pharma (FRA:609), the current Days Inventory is 25.79 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abionyx Pharma (FRA:609) Overvalued in 2026?
Based on GuruFocus' analysis, Abionyx Pharma stock appears to be overvalued.
The current stock price of €1.99 is trading 142.7% above its estimated GF Value™ of €0.82.
GuruFocus considers Abionyx Pharma to be Significantly Overvalued.
Key valuation signals for FRA:609:
Days Inventory: 25.79 (21% above median its 10-year median of 21.27)
GF Value™: €0.82 vs. price of €1.99 (142.7% above fair value)
Industry Position: 86% below the Biotechnology median (#36 of 638)
No single metric tells the full story. See the FRA:609 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.
19GF Score
Get the complete analysis for FRA:609
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:609 has been successfully added to your 
